第三届董事会第十二次会议决议公告 证券代码：301103 证券简称：何氏眼科 公告编号：2025-035 辽宁何氏眼科医院集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）第三届董事会第 十二次会议于 2025 年 9 月 19 日在公司会议室以现场及通讯相结合的方式召开。 经全体董事一致同意，本次会议豁免通知时限要求，已于 2025 年 9 月 16 日以口 头、电话等方式向全体董事送达。会议由董事长何伟先生主持，应出席董事 7 名，实际出席董事 7 名。公司部分高级管理人员列席了会议。本次会议的召集和 召开符合《中华人民共和国公司法》等法律、法规、规范性文件和《公司章程》 的有关规定，会议合法有效。 为进一步建立、完善公司激励约束机制以及员工与所有者共享机制，吸引和 保留优秀的管理人才和核心骨干，有效地将股东利益、公司利益和公司核心人员 个人利益结合在一起，促进各方共同关注公司的长远发展，确保公司发展战略与 经营目标的实现。根据《公司法》《中华人民共和国证券法》《上 ...

Core Points - He Eye Hospital (301103.SZ) has disclosed a draft for its 2025 restricted stock incentive plan, proposing to grant a total of 6.37 million shares, with an initial grant of 5.1 million shares [1] - The number of recipients for the initial grant will not exceed 240 individuals [1] - The grant price for the restricted stock is set at 13 yuan per share [1] - The effective period of the incentive plan will last from the date of grant until all shares are vested or become invalid, with a maximum duration of 60 months [1]

证券简称：何氏眼科 证券代码：301103 （草案）摘要 二零二五年九月 2025 年限制性股票激励计划（草案）摘要 声明 本公司及全体董事保证本激励计划草案及其摘要不存在虚假记载、误导性陈 述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 本公司所有激励对象承诺：如因公司信息披露文件中有虚假记载、误导性陈 述或重大遗漏，导致不符合授予权益或权益归属安排的，激励对象应当自相关信 息披露文件被确认存在虚假记载、误导性陈述或重大遗漏后，将因本激励计划所 获得的全部利益返还公司。 1 2025 年限制性股票激励计划（草案）摘要 辽宁何氏眼科医院集团股份有限公司 2025 年限制性股票激励计划 特别提示 一、辽宁何氏眼科医院集团股份有限公司（以下简称"何氏眼科"、"本公司" 或"公司"）2025 年限制性股票激励计划（草案）系依据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司股权激励管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号—— 业务办理》及其他有关法律、法规及规范性文件和《辽宁何氏眼科医院集团股份 有限公司章程》制订。 二、 ...

证券简称：何氏眼科 证券代码：301103 辽宁何氏眼科医院集团股份有限公司 2025 年限制性股票激励计划 声明 本公司及全体董事保证本激励计划草案及其摘要不存在虚假记载、误导性陈 述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 本公司所有激励对象承诺：如因公司信息披露文件中有虚假记载、误导性陈 述或重大遗漏，导致不符合授予权益或权益归属安排的，激励对象应当自相关信 息披露文件被确认存在虚假记载、误导性陈述或重大遗漏后，将因本激励计划所 获得的全部利益返还公司。 1 2025 年限制性股票激励计划（草案） 特别提示 一、辽宁何氏眼科医院集团股份有限公司（以下简称"何氏眼科"、"本公司" 或"公司"）2025 年限制性股票激励计划（草案）系依据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司股权激励管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号—— 业务办理》及其他有关法律、法规及规范性文件和《辽宁何氏眼科医院集团股份 有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票（第二类限制性股票）。股票 来源为辽宁何氏 ...

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

Core Viewpoint - He Eye Hospital's recent investment in the establishment of an industrial investment fund is strategically focused on enhancing its core business in eye health and exploring quality investment opportunities in the upstream and downstream of the industry chain as well as in emerging fields of new-generation healthcare [1] Group 1 - The company aims to strategically focus on its core business of eye health [1] - The investment is intended to facilitate professional division of labor within the industry [1] - The company is seeking quality investment targets in related emerging healthcare sectors [1]

Core Viewpoint - He Eye Hospital emphasizes its commitment to providing comprehensive eye health services through a model that integrates medical care, education, and research, aiming to enhance patient trust and societal contribution [1] Group 1: Company Overview - The company operates as a comprehensive eye health service institution, focusing on a full lifecycle of eye health management [1] - Established for over 20 years, the company has developed a robust experience in eye health services and a mature physician training system [1] Group 2: Business Philosophy and Goals - The company adheres to the business philosophy of "contributing to society, gaining patient trust, and achieving mutual development" [1] - The goal is to create a "Smart Bright City" by leveraging precision medicine and smart healthcare to provide patients with a new model of digital, all-scenario, and full-lifecycle eye health management [1] Group 3: Service Model - The company aims to promote the intelligent and personalized development of eye care services through its comprehensive three-tier eye health medical service model [1] - It focuses on delivering precise and convenient eye health management to patients [1]

Core Points - The company, He Eye Hospital Group, announced the release of lock-up shares totaling 74,936,340 shares, which accounts for 47.4201% of the total share capital [2] - The lock-up period for these shares was originally set for 36 months from the date of the initial public offering but has been extended by an additional 6 months due to the stock price conditions [2] - The new circulation date for the released shares is set for September 22, 2025 [2]

中原证券股份有限公司关于 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意辽宁何氏眼科医院集团股份有限公司 首次公开发行股票注册的批复》（证监许可〔2022〕126 号）同意注册，公司首 次公开发行人民币普通股（A 股）股票 3,050.00 万股，并于 2022 年 3 月 22 日在 深圳证券交易所创业板上市。公司首次公开发行前总股本 91,058,824 股，首次公 开发行股票完成后总股本为 121,558,824 股，其中有限售条件流通股数量为 92,632,517 股，占发行后总股本的 76.20%，无限售条件流通股数量为 28,926,307 股，占发行后总股本的 23.80%。 2022 年 5 月 19 日，公司 2021 年度股东大会审议通过《关于 2021 年度利润 分配及资本公积金转增股本预案的议案》，以公司总股本 121,558,824 股为基数， 向全体股东每 10 股派发现金股利 6 元（含税），共计分配现金股利 72,935,294.40 元，剩余未分配利润结转以后年度；以资本公积金转增股本的方式向全体股东每 10 股转增 3 股，转增 36,467,647 ...

证券代码： 301103 证券简称：何氏眼科 公告编号：2025-034 辽宁何氏眼科医院集团股份有限公司 关于首次公开发行前已发行股份解除限售并上市流通 的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为辽宁何氏眼科医院集团股份有限公司（以下简称 "公司"）首次公开发行前已发行的股份。本次解除限售股东户数共计 7 户，解除 限售股份数量为 74,936,340 股，占公司总股本的 47.4201%，限售期为自公司首 次公开发行股票并上市之日起 36 个月。因公司股票发行上市后 6 个月内连续 20 个交易日的收盘价均低于发行价，触发锁定期延长承诺的履行条件，该 7 名股东 的股份锁定期延长 6 个月至 2025 年 9 月 21 日。 2、本次解除限售股份的上市流通日期为 2025 年 9 月 22 日（星期一）。 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意辽宁何氏眼科医院集团股份有限公司 首次公开发行股票注册的批复》（证监许可〔2022〕126 号）同意注册，公司首 次公开发行人民币 ...